Skip to main content
. 2017 Jan 5;8(7):12108–12119. doi: 10.18632/oncotarget.14520

Figure 1A. Kaplan–Meier analysis for overall survival in group A (with EVBT) versus group B (with 3-DCRT).

Figure 1A

Mean and median survival time were 15.1 ± 1.0 months (95 % CI 13.2 – 17.1 months) and 11.7 ± 1.2 months (95 % CI 9.3-14.1 months) in group A compared to 10.4 ± 1.0 months (95 % CI 8.5 – 12.2 months) and 9.5 ± 1.8 months (95 % CI 5.9 – 13.1 months) in group B, respectively. The 12- and 24-month cumulative survival rates were 48.7%, 26.1% in group A and 31.4%, 3.4% in group B, respectively (p = 0.002, log rank test).